Cellectis (NASDAQ:CLLS) – Equities research analysts at SunTrust Banks issued their FY2022 earnings estimates for shares of Cellectis in a research report issued to clients and investors on Tuesday, March 13th, according to Zacks Investment Research. SunTrust Banks analyst P. Lawson anticipates that the biotechnology company will post earnings per share of $0.31 for the year.
A number of other research analysts also recently commented on the company. ValuEngine upgraded Cellectis from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. BidaskClub downgraded Cellectis from a “buy” rating to a “hold” rating in a research report on Wednesday, March 21st. Guggenheim began coverage on Cellectis in a research report on Friday, March 16th. They set a “neutral” rating for the company. Nomura increased their target price on Cellectis to $73.00 and gave the company a “buy” rating in a research report on Wednesday, March 14th. Finally, Zacks Investment Research downgraded Cellectis from a “hold” rating to a “sell” rating in a research report on Wednesday, February 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $42.67.
Shares of NASDAQ CLLS traded down $0.17 during midday trading on Thursday, reaching $28.83. 777,592 shares of the stock traded hands, compared to its average volume of 578,716. The company has a market capitalization of $1,035.80, a P/E ratio of -10.37 and a beta of 1.86. Cellectis has a one year low of $21.25 and a one year high of $38.85.
Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.12). The company had revenue of $6.91 million for the quarter, compared to analysts’ expectations of $10.10 million. Cellectis had a negative net margin of 298.01% and a negative return on equity of 35.63%.
Institutional investors and hedge funds have recently modified their holdings of the stock. Perceptive Advisors LLC bought a new stake in shares of Cellectis during the fourth quarter worth $10,203,000. BlackRock Inc. bought a new stake in shares of Cellectis during the fourth quarter worth $4,422,000. Sphera Funds Management LTD. lifted its position in shares of Cellectis by 71.1% during the third quarter. Sphera Funds Management LTD. now owns 348,736 shares of the biotechnology company’s stock worth $9,922,000 after purchasing an additional 144,972 shares during the last quarter. Bain Capital Public Equity Management LLC bought a new stake in shares of Cellectis during the fourth quarter worth $2,848,000. Finally, Millennium Management LLC lifted its position in shares of Cellectis by 1,356.2% during the fourth quarter. Millennium Management LLC now owns 104,290 shares of the biotechnology company’s stock worth $3,040,000 after purchasing an additional 97,128 shares during the last quarter. Institutional investors own 20.31% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Brokers Issue Forecasts for Cellectis’ FY2022 Earnings (CLLS)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/04/09/research-analysts-issue-forecasts-for-cellectis-sas-fy2022-earnings-clls.html.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Get a free copy of the Zacks research report on Cellectis (CLLS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.